Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions			12 Months Ended
		Nov. 20, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period			$ 526.4	$ 470.0
Acquisitions		$ 22.8		18.0	$ 80.0
Accretion			41.8	38.4
Payments			(44.9)
Reclassifications			0.0	0.0
Fair value loss (gain)	[1]		18.9
Foreign currency translation			(0.4)
Balance at end of period			564.6	526.4	470.0
Jai Pharma Limited
Schedule of Activity in Contingent Consideration [Roll Forward]
Fair value loss (gain)			12.6
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	[2]		35.0	20.0
Acquisitions	[2]		21.6	0.0
Accretion	[2]		0.1	0.0
Payments	[2]		(44.4)
Reclassifications	[2]		169.8	15.0
Fair value loss (gain)	[1],[2]		74.8
Foreign currency translation	[2]		0.0
Balance at end of period	[2]		256.9	35.0	20.0
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	[3]		491.4	450.0
Acquisitions	[3]	1.2		18.0
Accretion	[3]		41.7	38.4
Payments	[3]		(0.5)
Reclassifications	[3]		(169.8)	(15.0)
Fair value loss (gain)	[1],[3]		(55.9)
Foreign currency translation	[3]		(0.4)
Balance at end of period	[3]		$ 307.7	$ 491.4	$ 450.0
Other Noncurrent Liabilities | Jai Pharma Limited
Schedule of Activity in Contingent Consideration [Roll Forward]
Acquisitions		$ 18.0

[1] Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.

[2] Included in other current liabilities on the Consolidated Balance Sheets.

[3] Included in other long-term obligations on the Consolidated Balance Sheets.